RxDoctor Payments Data

Rubina Ahmed, MD

Internal Medicine · Taylor, MINPI 1376512418

Payments from drug & device makers

$584in general payments, 2019–2025

Across 26 payments — averaging $22.46 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$180
  • GSK$135
  • Teva Pharmaceuticals USA, Inc.$122
  • Lilly USA, LLC$48
  • Xeris Pharmaceuticals, Inc.$21
  • Lundbeck LLC$18
  • plus $60 from 4 others

What the payments were for

  • Food & beverage$584100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$584 in reported general payments places this provider in the 65th percentile of 4,567 internal medicine providers in Michigan.

See all internal medicine providers in Michigan

Medicare billing

Part B allowed, 2024
$11,953
Medicare patients
34
Services billed
143

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter114$120,436
EntrestoSacubitril/Valsartan49$55,827
OzempicSemaglutide43$55,629
JardianceEmpagliflozin48$46,078
TrulicityDulaglutide34$41,744
MounjaroTirzepatide33$32,927
LinzessLinaclotide33$26,207
EliquisApixaban20$25,705
MyrbetriqMirabegron39$25,494
JanuviaSitagliptin Phosphate17$18,910
TradjentaLinagliptin19$17,238
Janumet XrSitagliptin Phos/Metformin Hcl20$14,326
FarxigaDapagliflozin Propanediol15$12,656
Duloxetine Hcl217$10,845
Albuterol Sulfate HfaAlbuterol Sulfate125$8,017

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta$135$120,436114 claims
Lilly USA, LLCTrulicity, Mounjaro$48$74,67167 claims
Novo NordiskOzempic$180$55,62943 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 4,567 internal medicine providers in Michigan.

Other internal medicine in Taylor

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →